Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53

The heterogeneous nuclear ribonucleoprotein (hnRNP) K is an essential RNA and DNA binding protein involved in gene expression and signal transduction including DNA transcription, RNA splicing, RNA stability and translation. The role of hnRNP K in cancer is relatively understudied. However, several cellular functions strongly indicate that hnRNP K is involved in tumorigenesis. In this study, we investigated the altered protein expression and the subcellular distribution of the hnRNP K protein using tissue microarrays in pancreatic cancer. We showed an increased cytoplasmic hnRNP K in pancreatic cancer. This increase in hnRNP K protein occurs at the posttranscriptional level. We postulate that the cytoplasmic accumulation of hnRNP K will lead to silenced mRNA translation of tumor suppressor genes and thus contributes to pancreatic cancer development. We also demonstrated that knocking down of hnRNP K expression by siRNA inhibited pancreatic cancer cell growth and colony formation. hnRNP K was identified as a member of the p53/HDM2 pathway. Whether hnRNP K interacts with the mutant p53 is not known. Using two different pancreatic cancer cell lines, we can demonstrate that hnRNP K interacts with the mutant p53. The subcellular distribution and function of the mutant p53 and the interaction of hnRNP K/mutant p53 were affected by the Ras/MEK/ERK pathway, growth factors and the specific p53 mutations in pancreatic cancer cells. Since Kras is activated and p53 is mutated in most pancreatic cancers, these data unveiled an important new signaling pathway that linked by hnRNP K and mutant p53 in pancreatic cancer tumorigenesis.

[1]  G. Dreyfuss,et al.  Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. , 1993, The Journal of biological chemistry.

[2]  J. Hershey,et al.  The p34 cdc2 -related Cyclin-dependent kinase 11 Interacts with the p47 Subunit of Eukaryotic Initiation Factor 3 during Apoptosis* , 2003, The Journal of Biological Chemistry.

[3]  G I Murray,et al.  Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer , 2006, British Journal of Cancer.

[4]  A. Sakurada,et al.  hnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung. , 2003, Lung cancer.

[5]  Stephen P. Jackson,et al.  hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage , 2005, Cell.

[6]  J. Minna,et al.  Monoclonal antibodies that distinguish non-small cell from small cell lung cancer. , 1983, Journal of immunology.

[7]  M. Mandal,et al.  Growth Factors Regulate Heterogeneous Nuclear Ribonucleoprotein K Expression and Function* , 2001, The Journal of Biological Chemistry.

[8]  D. Perrotti,et al.  From mRNA Metabolism to Cancer Therapy: Chronic Myelogenous Leukemia Shows the Way , 2007, Clinical Cancer Research.

[9]  N. Tjandra,et al.  High precision solution structure of the C-terminal KH domain of heterogeneous nuclear ribonucleoprotein K, a c-myc transcription factor. , 1999, Journal of molecular biology.

[10]  L. Dwyer-Nield,et al.  Differential Expression and Localization of the mRNA Binding Proteins, AU‐Rich Element mRNA Binding Protein (AUF1) and Hu Antigen R (HuR), in Neoplastic Lung Tissue , 2000, Molecular carcinogenesis.

[11]  M. Tsao,et al.  Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. , 1996, The American journal of pathology.

[12]  J. Hershey,et al.  Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells , 2006, Oncogene.

[13]  A. Bhattacharyya,et al.  Loss of the eukaryotic initiation factor 3f in pancreatic cancer , 2008, Molecular carcinogenesis.

[14]  A. Maitra,et al.  Pancreatic Carcinogenesis , 2008, Pancreatology.

[15]  Galina Selivanova,et al.  MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. , 2009, Cancer cell.

[16]  W. Loging,et al.  Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53 , 1999, Oncogene.

[17]  F. Real,et al.  Comparative analysis of mutations in the p53 and K‐ras genes in pancreatic cancer , 1994, International journal of cancer.

[18]  S. Fukuda,et al.  Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer , 2006, Proteomics.

[19]  M. Zvelebil,et al.  Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons , 2004, Oncogene.

[20]  F. Mancini,et al.  MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. , 2007, Molecular cell.

[21]  J. Ostrowski,et al.  Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation , 2003, British Journal of Cancer.

[22]  E. Schmidt,et al.  hnRNP K Binds a Core Polypyrimidine Element in the Eukaryotic Translation Initiation Factor 4E (eIF4E) Promoter, and Its Regulation of eIF4E Contributes to Neoplastic Transformation , 2005, Molecular and Cellular Biology.

[23]  E. Małecka-Panas,et al.  Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[24]  D. Gewirtz Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage , 2000, Breast Cancer Research and Treatment.

[25]  Graeme I Murray,et al.  The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. , 2006, Biochimica et biophysica acta.

[26]  David Levens,et al.  Heterogeneous nuclear ribonucleoprotein K is a transcription factor , 1996, Molecular and cellular biology.

[27]  Kavita Shah,et al.  ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation , 2001, Nature Cell Biology.

[28]  P. Byrd,et al.  The interaction of the hnRNP family member E1B‐AP5 with p53 , 2005, FEBS letters.

[29]  G. Murray,et al.  Mortalin is over‐expressed by colorectal adenocarcinomas and correlates with poor survival , 2005, The Journal of pathology.

[30]  Jerzy Ostrowski,et al.  hnRNP K: One protein multiple processes , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[31]  J. Ostrowski,et al.  Characterization of hnRNP K protein-RNA interactions. , 2004, Journal of molecular biology.

[32]  M. Tsao,et al.  Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. , 2000, The American journal of pathology.

[33]  R. Young,et al.  The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. , 2007, Experimental cell research.

[34]  M. Tockman,et al.  Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Vicent,et al.  Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. , 2003, Lung cancer.

[36]  M. Mikuła,et al.  Landscape of the hnRNP K protein–protein interactome , 2006, Proteomics.

[37]  G. Stark,et al.  Hdm2 Nuclear Export, Regulated by Insulin-like Growth Factor-I/MAPK/p90Rsk Signaling, Mediates the Transformation of Human Cells* , 2006, Journal of Biological Chemistry.

[38]  J M Bujnicki,et al.  Editing of hnRNP K protein mRNA in colorectal adenocarcinoma and surrounding mucosa , 2006, British Journal of Cancer.

[39]  Rajendra K. Sharma,et al.  Identification of the SRC pyrimidine-binding protein (SPy) as hnRNP K: implications in the regulation of SRC1A transcription. , 2003, Nucleic acids research.

[40]  Y. Fukami,et al.  Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells , 2006, Journal of Cell Science.

[41]  H. Leffers,et al.  Identification, molecular cloning, expression and chromosome mapping of a family of transformation upregulated hnRNP-K proteins derived by alternative splicing. , 1994, Journal of molecular biology.